Development of Higher Molecular Weight of Recombinant Human Interferon Alpha-2a by Albumin Fusion Technology in Methilotropic Yeast Pichia Pastoris by Ningrum, Ratih Asmana et al.
  
 
Vol.7 (2017) No. 1 
ISSN: 2088-5334 
Development of Higher Molecular Weight of Recombinant Human 
Interferon Alpha-2a by Albumin Fusion Technology in Methilotropic 
Yeast Pichia Pastoris 
Ratih Asmana Ningrum#, Neng Herawati#, Andri Wardiana# 
#
 Research Center for Biotechnology Indonesian Institute of Science, Cibinong Science Center 
Jl Raya Bogor Km 46 Cibinong Bogor 16911, Indonesia 
 E-mail: ratih.asmana@gmail.com/rati004@lipi.go.id 
 
 
Abstract— Human interferon alpha-2a (hIFNα-2a) is a therapeutic protein that used in cancer and hepatitis B/C treatments. One 
main problem of using hIFNα-2a is the lack of good pharmacokinetic profile due to its low molecular weight. This research aims to 
develop recombinant hIFNα-2a fusion protein by using human serum albumin (HSA) to improve its molecular weight. The codon 
optimized open reading frame (ORF) encoding fusion protein constructed synthetically and inserted into pPICZαB expression vector 
and transformed into Escherichia coli XL1-blue. The characterized recombinant plasmid was linearized and transformed into 
methilotropic yeast Pichia pastoris GS115 and SMD 1168. The expression analysis showed that the best expression was achieved by 
protease deficient strain SMD1168. Molecular weight characterization informed that the fusion protein was 85 kDa in size as its 
theoritical size. Western blotting methods confirmed the identity of fusion protein based on the recognition by anti HSA and anti 
hIFNα-2 antibodies. This result strongly indicated that the fusion protein was successfully produced in Pichia pastoris. Protein 
quantification informed that the protein yield was 14 mg/L (OD600=2). Stability expression analysis showed that protein production 
was stable until 60th generations. Preliminary antiproliverative activity assay demonstrated that the fusion protein had 20% lower 
activity comparing to non fusion form.   
 




Cancer and hepatitis infection are major public health 
problem worldwide. It was reported that approximately 14.1 
million cancer cases occur worldwide with 8.2 million of 
death and about 64% of the death arise in developing 
countries. Currently, the global population for hepatitis is 6 
billions for Hepatitis B and 150 millions for Hepatitis C with 
1.5 million of death [1], [2]. hIFNα-2a is a cytokine that 
widely used in hepatitis and cancer treatments. It is a 
glycoprotein that consists of 165 amino acids with 19 kDa in 
size. Despite its wide biological activity as antivirus, 
antiproliferation, and immunomodulation, the protein still 
has major limitation due to rapid renal clearance [3]. As low 
molecular weight protein, the major elimination route of 
protein in the body is through renal filtration system by 
glomerulus [4].  Glomerulus filtration is selective to protein 
size and charge. Glomerulus filter is composed of three 
layers, namely the endothelial layer, the basal membrane, 
and the slit diaphragm. Glomerulus basement membrane has 
large protein molecules such as laminin, collagen type IV, 
entactin and sulfate proteoglycans that have negative charges 
and contribute to charge selectivity. Slit diaphragm has 4 x 
14 nm pore size which contributes on size selectivity [5].  
The elimination half-life of commercial unmodified 
rhIFNα-2a (Roferon®, Roche) which is given intravenously 
is 5 hours. The consequence of short half-life time is high of 
frequency treatment to maintain the effective concentration 
of the protein. The frequency of rhIFNα-2a treatment is 
dependent upon the diseases. The frequency of treatment for 
hepatitis B or C is three times per week for 24 to 48 weeks 
and for the oncological indication is daily from several 
months to a year or longer [6]. Moreover, frequent treatment 
produces several dose dependent side effects, such as 
toxicity to the skin, nervous, endocrine, and immune 
problems [3], [6], [7]. 
The strategies to improve the elimination half-life time of 
rhIFNα-2a have been done with a wide variety of protein 
modification approach, such as higher molecular weight by 
pegylation, protease resistant variants by amino acid 
substitution and more negatively charge by glycosilation. 
The most successful modification is protein conjungation by 
polyethylene glycol (PEG). The commercial pegylated 
protein is a larger molecule, PEGASYS (Hoffman La Roche, 
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UK), which has branched 40 kDa PEG molecule with 70 
hours of elimination half life. PEGASYS decreases the 
therapy frequency for only once a week though it only 
retains 7% of E. coli derived protein activity [6], [7]. The 
most shortcoming of pegylation is product heterogeneity due 
to different PEG binding position in the protein. Another 
modification in rhIFNα-2a is glycosylation which not only 
increases the protein molecular weight but also changes the 
total charge into more negative [3].  
Albumin-fusion technology is a rational, simple and 
flexible alternative platform to modify rhIFNα-2a. The 
technology is purposed to increase the protein molecular 
weight through a fusion between rhIFNα-2a and human 
serum albumin (HSA).  HSA is the major protein in blood 
plasma that is produced by the liver and plays a role in 
maintaining blood osmolarity and carry small molecules [8]. 
HSA is chosen because it has a 9 day long half-life in the 
body, widely distributed and is not immunogenic. Moreover, 
it may improve the solubility and stability of the protein [9]. 
There are some proteins that used albumin-fusion 
technology to improve molecular weight and elimination 
half-life, such as insulin, p53, recombinant factor VIII, 
recombinant factor IX, Somatostatin, VEGF165b, growth 
hormone, granulocyte colony stimulating factor, interferon 
alpha-2b, interleukin 2, glucagon-like peptide and β-
natriuretic peptide [10], [11], [12], [13], [14], [15], [16]. 
A previous study in Albuferon (HGSI, Novartis) as a 
fusion protein of rhIFNα2b with HSA reported that the 
protein elimination half-life is increasing until 159 hours 
although the protein failed and withdrawn in clinical assay 
phase II. This long elimination half-life can decrease the 
frequency of therapy into once in two weeks [16].  The 
albumin fusion technology has widely used as a fusion 
partner to extend in vivo half-life of protein therapeutics and 
both the N terminal and C terminal. Zhao et al claimed that   
HSA fusion at the N-terminal of rhIFNα-2a caused 
heterogeneity due to the disruption of the disulfide bond 
between cysteine at positions 1 to 98. This causes instability 
that promotes aggregation so the formulation must be in 
lyophilized form which requires additional freeze-drying 
process, additional time and cost. Instability of these proteins 
also causes low recovery during the purification process. 
Heterogeneity in HSA-hIFNα-2b fusion protein can be 
avoided by adding a linker between the two proteins or 
changing the orientation of HSA fusion at the N-terminal 
into C-terminal [8], [9]. 
This research was purposed to develop higher molecular 
weight of rhIFNα-2a by using HSA fusion technology in 
methilotropic yeast Pichia pastoris. The codon optimized  
open reading frame encoding fusion protein with HSA 
orientation at the C terminal of rhIFNα-2a. Two different 
strains of Pichia pastoris were used : GS115 and protease 
deficient strain SMD1168 as protein production host to 
obtain best expression level.  So far there was no study 
reported the use of two different hosts for production of 
rhIFNα-2a-HSA in Pichia pastoris. Yang et al used 
SMD1168 to produce human interferon alpha-2b-
thymosinα1 fusion protein and Yu et al applied the same 
strain to obtain interferon alpha-2b-HSA [17], [18]. Several 
publications also reported GS115 as production host of 
interferon alpha-2b-HSA fusion protein [8], [18], [19].  
II. MATERIALS AND METHODS 
A. Strains and Media 
The E. coli that used for cloning purpose was XL1blue 
(Stratagene, USA). The cultivation media was low salt LB 
(1 % tryptone, 0.5 % yeast extract and 1% NaCl) and the 
selection media was low salt LB agar with 25 μg/ μL of 
zeocin (Invitrogen, USA). Pichia pastoris that used as 
production host were wildype X33, mutant GS115 and 
protease deficient SMD1168 (Invitrogen, USA). Cultivation 
media was YPD (1% yeast extract, 2% peptone, 2% 
dextrose), screening media was YPDS (1% yeast extract, 2% 
peptone, 2% dextrose, 1M sorbitol) containing zeocin from 
500 to 2000 μg, and expression medias were BMGY (1% 
yeast extract, 2% peptone, 100mM potassium phosphate pH 
6, 1.34% YNB, 1% glycerol, 0.2% Biotin), and BMMY that 
consist of 1% yeast extract, 2% peptone, 1.34% YNB, 0.2% 
Biotin and 0.5% methanol, respectively. The protease 
inhibitor that added during the expression was a complete 
ultra-tablet (Roche, Germany). 
B. Construction of ORF and Transformation into P. 
pastoris 
Codon optimized ORF encoding fusion protein was 
constructed synthetically by IDT (Singapore) and inserted in 
PUC-IDT cloning vectors. The ORF was sub cloned into 
pPICZαB expression vector and transformed into E. coli 
XL1 blue. The transformants were selected in low salt LB 
agar containing 25μg/mL of zeocin. Recombinant plasmids 
were isolated and characterized based on their molecular 
weight and XhoI-EcoR1 restriction sites. The recombinant 
plasmid was linearized by SacI restriction enzyme and 
purified by using phenol-chloroform precipitation. 10 µg of 
linearized plasmid was transformed into Pichia pastoris cells 
by electroporation (BioRad) at 2000V. The transformants 
were selected in YPDS medium containing 100 µg/ml of 
zeocin at 30°C for 24-48 h. The selected colonies were 
further screened to select the highest copy number in YPDS 
medium containing 500, 1000 and 2000 µg of zeocin.  
C. Expression Analysis and Protein Characterization 
A single colony was cultivated in 2 ml BMGY at 30°C 
and 250 rpm for 24 h. The pellet was collected, resuspended 
in 2 ml BMMY (OD=1) and cultivated at the same condition. 
Methanol (0.5%) was added at 24 h of cultivation time. The 
supernatant was collected by centrifugation at 1500 x g for 5 
min. Protein supernatant was collected and characterized by 
SDS- PAGE and Slot Blot methods to monitor protein 
expression and verify its identity. SDS-PAGE was 
performed by using 10% (w/v) polyacrylamide gel and 
coomassie blue staining solution (BioRad). 1: 1000 dilution 
of mouse anti IFNα-2 (Merck 407290-500 UGCN, Germany ) 
or 1:1000 dilution of mouse anti HSA (Sigma) and 1: 7500 
dilution of anti mouse IgG alkaline phosphatase conjugate 
(Promega, USA) with NBT/BCIP detection (Merck, 
Germany) were applied in Slot Blot method. 
D. Stability Expression, Overproduction, and Purification 
The replica plating method was used to check the stability 
expression of ORF encoding fusion protein. We used YPD 
media containing 100 μg/mL of zeozin. The expression 
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monitoring was performed for each 10th generation. 
Overproduction was applied by using shake flask method 
with 50 mL of BMMY media. A single colony was grown 
overnight in 25 ml BMGY medium at 30°C and 250 rpm 
until log phase (OD600= 2-6). The culture was centrifuged at 
1500 x g for 5 min. The pellet was resuspended in 50 ml 
BMMY medium (OD600 = 1.0 containing 0.5% methanol as 
inducer). We used two different harvesting time 24 h and 48 
h after the induction. The 48h harvesting time was carried 
out by repeating the induction after 24 h cultivation time. 
Harvesting was performed by centrifugation at 1500 x g for 
5 minutes at room temperature. Supernatant containing 
fusion protein was collected and concentrated 10X (v/v) by 
using tangential filtration system with 10 kDa molecular 
weight cut off. The concentrated protein was purified by 
using affinity chromatography method by blue sepharose 6 
fast flow (Capto blue, GE healthcare, Germany).  Sample pH 
was adjusted to neutral pH, filtered through 0.22 μm filter 
and loaded into the column. The column was washed with 
starting buffer (50 mM sodium phosphate buffer pH7) to 
remove weakly bound impurities. The fusion protein was 
eluted from the column by using 50 mM sodium phosphate 
and 1.5 M KCl pH 7.  Purified protein was characterized 
based on its molecular weight and identity by SDS PAGE 
and Western Blotting Methods. Protein binichoninic assay 
was used to quantify the purified protein by using Bovine 
Serum Albumin. 
E. Antiproliferation Assay 
MCF-7 cells (obtained from mammalian cell culture 
laboratory, Indonesian Institutes of Sciences) were thawed 
and washed with 9 mL of DMEM medium containing 
penicillin (100 units/mL) and streptomycin (100 mg/mL). 
Cells were grown in the same medium containing 10% fetal 
bovine serum (FBS) at 37°C and 5% CO2. After 90% of 
confluency, the cells were washed with phosphate buffer 
saline (1.15 g Na2HPO4; 0.2g KH2PO4; 8g NaCl and 0.2g 
KCl perliter, pH 7.2) and detached with 500 µL of trypsin-
EDTA(0.25% trypsin in 0.53 mM EDTA) at 37°C for 5 min. 
The cells were transferred into a 96 well (3000 cell/well) or 
24 well plate (15.000/ well) for further study. The cells were 
grown overnight in DMEM media containing penicillin-
streptomycin with 5% FBS, washed with 100 µL of PBS and 
treated with 1 µM tamoxifen (Merck) overnight. Further 
treatment was applied by various concentration of hIFNα-2b 
for 5 days. rhIFNα-2b standard was applied to validate the 
assay. The treatment conditions were based on a report by 
Lindner and Borden [20] with some modifications. Treated 
cells in 96 well plates were washed twice with100 µL of 
PBS. 100µL of DMEM with 5% FBS containing MTT (with 
final concentration 0.5 mg/mL) was added to each well. 
Cells were then incubated for 3 hours and the medium was 
discarded. Formazan crystals formed at the bottom of the 
well were dissolved in 100 µL of SDS 10%. The cells were 
incubated for overnight. The reaction was stopped by 0.01 M 
HCl and dissolved formazan was measured at 570 nm. The 
percentage of the viable cell was compared to control 
(untreated cells). The experiments were done in triplicates in 
three dependent experiments [21]. 
 
III. RESULTS AND DISCUSSION 
The fusion protein was produced extracellularly in Pichia 
pastoris. The codon optimized ORF encoding fusion protein 
was constructed synthetically. The synthetic ORF encoding 
HSA-hIFNα-2a was 2292 bp in size and inserted in 
pUCIDT-AMP vector with ampicillin as a selectable marker. 
As shown in Fig. 1, the constructed sequence was consists of 
XhoI and EcoRI as restriction sites,  protease cleavage site of 
alpha-factor signal sequence in pPICZαB and ORF encoding 
human interferon alpha2a  that was fused with human serum 
albumin ORF at its C terminus (Fig. 1). Zhao et al (2008) 
reported that N terminus of hIFNα2b directly fused to C 
terminus HSA resulted in heterogenicity, we applied altering 
the orientation by fused HSA into C terminus of hIFNα-2a. 
It was identified that the heterogenicity of hIFNα-2b-HSA 
caused by disruption of disulfide bridge formation between 
Cys1 and Cys98 so that the fusion protein was unstable and 
prone to form aggregates [19]. To avoid the immunogenicity 
of the fusion protein, we eliminated the linker between the 
two proteins.  
pPICZαB was used as expression vector that contains α-
factor secretion signal. The ORF constructed to be in frame 
with α-factor signal sequence to produce extracellular 
protein and applied sub cloning. The sub cloning was 
performed to insert the ORF into expression vector 
pPICZαB expression vector contains tigthly regulated AOX1 
promoter that strongly repressed by glucose, glyserol or 
ethanol [22], [23], [24].  As described in vector map, the 
processing of α-factor matting signal sequence in pre fusion 
protein is performed by KEX2 and STE13 gene products. 
KEX2 cleavage occuring between arginine and glutamine in 
the sequence Glu-Lys-Arg-Glu-Ala-Glu-Ala. The Glu Ala 
repeats are furtherly cleavage by STE13. The ORF flushed 
with KEX2 cleavage site to obtain fusion protein with N 
native terminus hIFNα-2a.  
Transformation in E. coli XL1 blue resulted in 101 
transformants in low salt LB agar containing zeocin as 
selection media. Only 6 transformants harboring 
recombinant plasmid as expected. Molecular weight and 
restriction site characterizations of transformants number 1 
showed that recombinant plasmid containing the ORF with 
correct size as demonstrated in Fig. 2 (A). The recombinant 
plasmid was further linearized by using SacI and purified by 
phenol chloroform precipitation as showed in Fig. 2 (B). 
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Fig. 1 The construction of synthetic ORF encoding fusion protein 
 
 
Fig. 2 Recombinant plasmid characterization, A. Characterization of 
recombinant plasmid containing fusion protein ORF by XhoI and EcoRI 
restriction enzyme, B. Linearization of recombinant plasmid containing 
fusion protein ORF by SacI restriction enzyme 
 
Purified recombinant plasmid containing fusion protein 
ORF was transformed into Pichia pastoris by 
electroporation and transformants were selected in the 
gradual concentration of zeocin. 
The ORF was transformed into GS115 and SMD1168 
strains. GS115 is a mutant that has a mutation in the 
histidinol dehydrogenase gene (his4) that prevents it from 
synthesizing histidine. As host-specific proteases determine 
effective production and purification of heterologous 
proteins from yeasts, this research also used SMD1168 as 
protease deficient mutant that lack of proteinase A (pep4) 
activity. 
There were 11 selected transformants (9 transformants of 
SMD1168 and 2 transformants of GS115) to be observed in 
expression analysis.  Protein overproduction was performed 
by applying methanol as an inducer. All transformants gave 
a positive result at 24 and 48 h of harvesting time using 
mouse anti HSA antibody in dot blot analysis (data not 
shown). This result strongly indicated that the targeted 
fusion protein was produced in Pichia pastoris GS115 and 
SMD1168. Further characterization was undertaken by SDS 
PAGE and Western Blot analyses based on protein 
molecular weight and identity. The electrophoregram profile 
informed that each strain produced a fusion protein with 85 
kDa in size. We also observed the protein overproduction at 
two different harvesting time (24h and 48h) for SMD1168 
transformants as shown by Fig. 3 (A, B, C, D) and GS115 
transformants as shown by Fig. 3 (E, F), The production 
generated better protein level at 48h (Fig. 3 C and E). 
Several bands that also produced with a smaller size on 
Western Blot analysis indicated that the fusion protein was 
degraded by protease activity.  
 
 
Fig. 3 Characterization of the fusion protein.  A and B = SMD1168 
transformant no 1 to 9 at 24 h of harvesting time; C and D = transformant 
no 1 to 9 at 48 h of harvesting time; E and F = GS115 transformant no 1 and 
3 at 24 h and 48h of harvesting time. The bands in the red box were the 
fusion protein 
 
The secreted fusion protein degraded due to activity of 
extracellular proteases, cell bound proteases or intracellular 
proteases from lysed cells. Proteolysis is a major problem of 
protein production in Pichia pastoris because it reduces 
protein yield, deprives biological activity and contaminates 
the product with degradation fragments that have similar 
physicochemical and affinity characteristic [25]. There are 
several proteases that mostly produced in Pichia pastoris, 
namely proteinase A, proteinase B, carboxylpeptidase and 
aminopeptidase [26]. Several strategies to inhibit proteolysis 
activity have been reported, such as protein engineering [27], 
optimization of fermentation parameters (pH, temperature 
and growth rate), modification of culture media composition 
(rich media, additional amino acid or peptone, lowering salt 
concentration as well as soytone addition) [19] and the use of 
protease deficient strain. Ahmed [23] stated that in some 
cases optimization of fermentation and protein enginnering 
have been failed to overcome the proteolysis problem so the 
use of protease deficient strain can be more promising. Its 
use not only reduces proteolysis that lowering protein yield 
in production but also avoid time consuming and 
complicating downstream process due to degradation 
product [23], [26].  
In this research, the use of SMD1168 to produce fusion 
protein was still not completely deprived the proteolysis 
problem. Protein profile on electrophoregram still showed 
some degradation fragments which indicated that the knock 
out of pep4 that encodes proteinase A did not completely 
eliminate the proteolysis. pep4 encodes a major vacuolar 
aspartyl protease which is able to activate itself as well as 
other proteases such as carboxypeptidase Y (PRC1) and 
proteinase B (pRb1) [26].  This indicated that the 
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degradation that still occured in our fusion protein did not 
caused by proteinase A or B as well as PRC1.  
Several studies reported the role of yapsin 1 protease in 
degradation of recombinant protein produced in the host [28], 
[29], [30], [31].  Yapsin is a glycosylphosphatidylinositol 
(GPI)-linked aspartyl proteases family that have the ability 
to cleave protein at the C-terminal side of basic amino acids. 
Kerry et al [30].  reported that HSA produced in 
Saccharomyces cerevisiae was truncated by yapsin1 (YPS1) 
protease. This report was in line with Yao et al [32] that 
stated YPS1 disruption gave a partial reduction of HSA 
degradation. Wu [31] also claimed that the disruprion of 
YPS 1 and pep4 reduced proteolytic degradation of secreted 
HSA-parathyroid hormone in Pichia pastoris GS115.  
Protease inhibitor was also used to reduce the protease 
activity. The inhibitor was added at 0 to 3 h after initial 
production to obtain optimal condition. To check the 
proteolysis profile that results in smaller protein fragments, 
Western Blot analysis was used. The result informed that the 
best production level was achieved at 3 h after initial 
production (Fig. 4). The combination of SMD1168 strain 
and protease inhibitor reduced proteolysis signifficantly. The 
protease inhibitor is able to inhibit aspartic proteases, as well 
as serine and cysteine proteases. This strongly indicated that 
the proteolytic activity of yapsin as aspartic protease was 
inhibited by antiprotease so that the presence of degradation 
fragments was minor. It was found that the addition of 
protease inhibitor at 0 to 30 minutes after expression may 
result in AOX1 promoter repression so the protein did not be 
produced. So far there was no study reported the AOX1 
repression caused by protease inhibitor. ImageJ software  
was applied (free downloaded at 
http://imagej.en.softonic.com) to determine best expression 
level (data not shown). The highest Area Under the Curve 
(AUC) was obtained in 3 h of inhibitor addition. Protein 
purification by affinity chromatography column showed that 
the fusion protein has been purified as shown in Fig. 5. The 
protein quantity determination informed that the yield of the 
fusion protein was 14 mg/L. The total yield of our fusion 
protein was 14 mg/L (OD600=2). Because this research still 
used low OD in protein production, so the result was lower 
than another study that produced HSA-VEGF165b fusion 




Fig. 4  Overproduction of fusion protein by using protease inhibitor. The 




                   
Fig. 5  Purification of the fusion protein by using affinity chromatography.  
E1 to 5 = eluate 1, 2, 3, 4 and 5. 
 
                      
Fig. 6  Stability of fusion protein production in 60th generation  
1=control , 2=fusion protein from GS115 and 3=fusion protein from 
SMD1168 
 
The ORF expression was monitored in Pichia pastoris 
until 60th generation. The expression stability is the most 
important thing in protein production. ORF expression 
stability was performed to monitor the stability integration of 
the ORF into Pichia pastoris genome. The stable 
transformants were generated by homologous recombination 
between the transforming ORF and regions of homology 
within the genome [33]. There was no significant difference 
in expression among the generations which strongly 
indicated that the fusion protein production of recombinant 
Pichia pastoris was stable (Fig. 6).  The stability analysis 
also informed that SMD1168 gave better expression level 
comparing to GS115.  
It has been known that protein modification often results 
in decreasing biological activity due to protein structure 
alteration. The effect of HSA fusion into hIFNα-2a 
antiproliferative activity by using MCF-7 cell line. MCF-7 is 
human breast adenocarcinoma and ER positive cell line. At 
this preliminary antiproliferative assay, unmodified hIFNα-
2a from previous research was used as a standard. There was 
lowering antiproliferative activity of fusion protein 
comparing to its unmodified form (Fig. 7). The 




 Fig. 7  Antiproliferative activity of fusion and non fusion hIFNα-2a 
 
The biological activity of interferon type I occurs through 
the IFNAR1 and IFNAR2 receptors  [34,35]. The two 
receptor-associated tyrosine kinases Tyk2 and Jak1 will be 
activated, which subsequently recruit and activate the 
cytoplasmic factors belonging to the signal transducer and 
activator of transcription (STAT) family of proteins  [36,37].  
STAT subsequently translocated with interferon regulating 
factor-9 (IRF-9 or P48) to the cell nucleus. The protein 
complex known as IFN-Stimulated Gene Factor 3 (ISGF-3) 
can activate interferon stimulating response element (ISRE). 
Two phosporylated sub unit of Stat 1 form alpha activation 
factor that binds to gamma activation sequence (GAS). 
These induce transcription of hundreds of interferon-
stimulated genes (ISGs) that involve in antiproliferative [38, 
39], [40].  
Preliminary antiproliferative determination performed 
using a combination with tamoxifen (tmx). According to the 
previous study, tmx can modulate the anticellular response 
to rhIFNα-2 rather than the opposite.  Tamoxifen is a cell-
permeable and reversible inhibitor of protein kinase C. It 
induces apoptosis in human malignant glioma cell lines and 
inhibits prostate cancer cell growth by induction of p21 
protein. Tamoxifen is a potent synthetic anti-estrogenic 
agent. It is cytostatic for estrogen-dependent cell line. 
Estradiol binds to estrogen receptor (ER) in ER positive cell 
and induces transcription to promote growth. Tamoxifen 
competes with estrogen for binding to the receptor so growth 
inhibition occurs [38]. 
The antiproliferative determination showed that fusion 
protein has lower activity comparing to unmodified form. 
The result informed that at various concentrations used, the 
activity of the fusion proteins was about 20% lower. It is too 
early to state that our fusion protein has no much different 
activity with the unmodified form, so further analysis may 
need to complete and strengthen the result. Our result was in 
line with other studies about modified hIFNα2. Bailon et al.  
reported that pegylated hIFNα-2a retains only 7% of 
antiviral activity comparing to unmodified form [6]. 
Subramanian et al (2005) also stated that HSA fusion 
hIFNα-2b was less potent comparing to unmodified form but 
gave greater antiviral activity comparing to pegilated hIFNα-
2b [16].  
Currently, hIFNα-2a is still a potential therapeutic protein 
to be developed. Many diseases stated the urgency of using 
the protein in future direction treatment, such as hepatitis B 
and C [41], [42], systemic lupus erythematosus [43] and 
renal cell carcinoma [44]. HSA fusion protein is one of 
modification studies to develop hIFNα-2a. The protein will 
be further characterized and pharmacokinetic determined. 
IV. CONCLUSIONS 
The higher molecular weight of interferon alpha2a by 
human serum albumin fusion was successfully produced in 
Pichia pastoris  with 85 kDa in size. The ORF expression 
was stable until 60th generations.  The yield of purified form 
was 14 mg/L. At preliminary antiproliferative activity 
determination, the fusion potein has a potential activity that 
only 20% lower comparing to unmodified form.  
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